News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
News Conference News ACC 2024 EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2 Shelley Wood April 07, 2024
News Conference News ACC 2023 Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR Michael O'Riordan March 13, 2023
News Conference News ACC 2023 Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT Yael L. Maxwell March 07, 2023
News Conference News ACC 2021 Social Determinants of Health Tied to Fewer COVID-19 Precautions in CVD Patients Caitlin E. Cox May 07, 2021
News Conference News ACC 2020 Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes Yael L. Maxwell March 30, 2020
News Conference News ACC 2020 Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach Todd Neale March 28, 2020
News Conference News ACC 2019 New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin Shelley Wood March 26, 2019
News Conference News ACC 2019 Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom Michael O'Riordan March 20, 2019
News Conference News ACC 2018 Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS Michael O'Riordan March 12, 2018
News Conference News ACC 2018 ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last Shelley Wood March 05, 2018
News Conference News ACC 2017 High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI Michael O'Riordan March 21, 2017
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017